Refreshed…
hk7a-jbxa
v7z4-v2s8
mrth-vbs8
gmup-gch2
yb58-3xpc
2v7y-cvbw
d95n-h8d4
st7m-vrxa
xjbh-6anj
hgxh-yn5k
j24p-bj78
9xpr-wkpn
zc9w-cy7e
np24-hrqu
59lq-5skp
bys6-bdtn
auqu-wl3j
rmgd-hedk
arks-v3s8
xh35-ekcm
hk7a-jbxa
v7z4-v2s8
mrth-vbs8
gmup-gch2
yb58-3xpc
2v7y-cvbw
d95n-h8d4
st7m-vrxa
xjbh-6anj
hgxh-yn5k
j24p-bj78
9xpr-wkpn
zc9w-cy7e
np24-hrqu
59lq-5skp
bys6-bdtn
auqu-wl3j
rmgd-hedk
arks-v3s8
xh35-ekcm
Hello to new arrivals at Bluesky.
Here are some free album download codes, this one seems like a good intro to Third Kind…
bandcamp.com/yum
fv9x-hawk
sz7m-v2la
s357-6dvb
h6xh-y7ak
nq24-hrju
bks6-bdyn
afks-v3c8
hjx9-78hg
jfcz-5nq3
nhex-v7tl
lqrs-6euj
48ls-yuak
euse-3qf8
gwqf-c9en
ys8l-wtfe
Here are some free album download codes, this one seems like a good intro to Third Kind…
bandcamp.com/yum
fv9x-hawk
sz7m-v2la
s357-6dvb
h6xh-y7ak
nq24-hrju
bks6-bdyn
afks-v3c8
hjx9-78hg
jfcz-5nq3
nhex-v7tl
lqrs-6euj
48ls-yuak
euse-3qf8
gwqf-c9en
ys8l-wtfe
November 14, 2024 at 10:07 AM
Refreshed…
hk7a-jbxa
v7z4-v2s8
mrth-vbs8
gmup-gch2
yb58-3xpc
2v7y-cvbw
d95n-h8d4
st7m-vrxa
xjbh-6anj
hgxh-yn5k
j24p-bj78
9xpr-wkpn
zc9w-cy7e
np24-hrqu
59lq-5skp
bys6-bdtn
auqu-wl3j
rmgd-hedk
arks-v3s8
xh35-ekcm
hk7a-jbxa
v7z4-v2s8
mrth-vbs8
gmup-gch2
yb58-3xpc
2v7y-cvbw
d95n-h8d4
st7m-vrxa
xjbh-6anj
hgxh-yn5k
j24p-bj78
9xpr-wkpn
zc9w-cy7e
np24-hrqu
59lq-5skp
bys6-bdtn
auqu-wl3j
rmgd-hedk
arks-v3s8
xh35-ekcm
#$VRXA CEO & Co-Founder, Christoph Antz, PhD, will be participating in a panel on "Developing the Next Generation of Innovations in Antibody-Drug Conjugates (ADCs)" as part of the ICR Healthcare Conference Series.
Register here: icr.swoogo.com/adc/begin
#ADCs #Biopharma
Register here: icr.swoogo.com/adc/begin
#ADCs #Biopharma
September 22, 2026 at 1:48 PM
#$VRXA CEO & Co-Founder, Christoph Antz, PhD, will be participating in a panel on "Developing the Next Generation of Innovations in Antibody-Drug Conjugates (ADCs)" as part of the ICR Healthcare Conference Series.
Register here: icr.swoogo.com/adc/begin
#ADCs #Biopharma
Register here: icr.swoogo.com/adc/begin
#ADCs #Biopharma
🎉 #VERAXA Biotech begins trading today on NASDAQ (#$VRXA)!
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
June 11, 2026 at 1:30 PM
🎉 #VERAXA Biotech begins trading today on NASDAQ (#$VRXA)!
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.
Read more: bit.ly/4ooC21e
This is America ... right now ... I wonder why they feel so empowered?
www.youtube.com/watch?v=vrxa...
www.youtube.com/watch?v=vrxa...
Demonstrators seen waving Nazi flags
YouTube video by WLNS 6 News
www.youtube.com
November 12, 2024 at 1:56 PM
This is America ... right now ... I wonder why they feel so empowered?
www.youtube.com/watch?v=vrxa...
www.youtube.com/watch?v=vrxa...
friend shared this with me and there's so many layers to this remix that I'm coming to terms with www.youtube.com/watch?v=vrxA...
James Brown is Dead or Alive!?!?-2010
YouTube video by Mohican Sandbag - Topic
www.youtube.com
April 5, 2025 at 12:35 PM
friend shared this with me and there's so many layers to this remix that I'm coming to terms with www.youtube.com/watch?v=vrxA...
🎵 Heartflare — by Craze Mode On
Bright, cinematic–electronic energy music for gaming & edits⚡
🎧 Free to use (credit required)
▶️ youtu.be/58kHTD-vRxA
#Heartflare #GamingMusic #FreeMusic #CrazeModeOn #NoCopyrightMusic #Creators #2026Music #musicchallenge
Bright, cinematic–electronic energy music for gaming & edits⚡
🎧 Free to use (credit required)
▶️ youtu.be/58kHTD-vRxA
#Heartflare #GamingMusic #FreeMusic #CrazeModeOn #NoCopyrightMusic #Creators #2026Music #musicchallenge
Heartflare - Craze Mode On
YouTube video by Craze Mode On
youtu.be
January 15, 2026 at 6:15 PM
🎵 Heartflare — by Craze Mode On
Bright, cinematic–electronic energy music for gaming & edits⚡
🎧 Free to use (credit required)
▶️ youtu.be/58kHTD-vRxA
#Heartflare #GamingMusic #FreeMusic #CrazeModeOn #NoCopyrightMusic #Creators #2026Music #musicchallenge
Bright, cinematic–electronic energy music for gaming & edits⚡
🎧 Free to use (credit required)
▶️ youtu.be/58kHTD-vRxA
#Heartflare #GamingMusic #FreeMusic #CrazeModeOn #NoCopyrightMusic #Creators #2026Music #musicchallenge
Today's order flow report: $SDEV (+24.04%) triggers short squeeze risk. $ENRD (+19.28%) has high execution risk. $MINE (+18.75%) shows severe illiquidity. $VRXA (+15.65%) confirms momentum on relative volume. Watch low-float spreads. #DayTrading #OrderFlow
July 2, 2026 at 3:26 PM
Today's order flow report: $SDEV (+24.04%) triggers short squeeze risk. $ENRD (+19.28%) has high execution risk. $MINE (+18.75%) shows severe illiquidity. $VRXA (+15.65%) confirms momentum on relative volume. Watch low-float spreads. #DayTrading #OrderFlow
Intraday Alert: $SDEV (+30.77%) leads with short squeeze potential, while $VRXA (+18.26%) registers a 41.4x relative volume surge. $WBX (+22.35%) shows low-float action, but $MINE (+18.98%) lacks volume confirmation. Watch execution risk. #daytrading #orderflow
July 3, 2026 at 3:27 PM
Intraday Alert: $SDEV (+30.77%) leads with short squeeze potential, while $VRXA (+18.26%) registers a 41.4x relative volume surge. $WBX (+22.35%) shows low-float action, but $MINE (+18.98%) lacks volume confirmation. Watch execution risk. #daytrading #orderflow
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to bring AI-driven tools to its BiTAC cancer drug platform, aiming to improve tumor targeting and reduce toxicity by analyzing large clinical datasets. A key step forward in precision oncology. #Oncology #Biotech
July 13, 2026 at 5:04 PM
VERAXA Biotech (NASDAQ: VRXA) partners with Ardigen to bring AI-driven tools to its BiTAC cancer drug platform, aiming to improve tumor targeting and reduce toxicity by analyzing large clinical datasets. A key step forward in precision oncology. #Oncology #Biotech
🧬 #$VRXA looks ahead: doubling down on its BiTAC® platform, with VXA-102 targeted IND/CTA-ready by early 2028. Plans to monetize non-BiTAC assets to fuel growth, plus VXA-901 (AML) & HER2-ADC open for partnering.
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
July 6, 2026 at 2:32 PM
🧬 #$VRXA looks ahead: doubling down on its BiTAC® platform, with VXA-102 targeted IND/CTA-ready by early 2028. Plans to monetize non-BiTAC assets to fuel growth, plus VXA-901 (AML) & HER2-ADC open for partnering.
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
Read more: bit.ly/4eZPKU6
#Biotech #Oncology
📈 VRXA (Veraxa Biotech Holding AG) +11.1% since we peeled back the filing
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
July 7, 2026 at 9:19 PM
📈 VRXA (Veraxa Biotech Holding AG) +11.1% since we peeled back the filing
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
Filed: Jul 7, 2026 | 12:07 ET | Now: Jul 7, 2026 | 17:18 ET
At filing: $2.70 to Now: $3.00
Score: 7/10 | Positive
Headlines are late. Filings aren't.
Read the original breakdown (sourced from Wiseek):
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
September 10, 2026 at 8:00 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Dr. Christoph Erkel as CSO to advance its proprietary BiTAC T cell engager platform toward clinical development. Preclinical data at AACR showed promising selective cancer cell activity. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
September 8, 2026 at 8:01 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance expertise to accelerate its next-gen cancer therapy pipeline and proprietary BiTAC platform. #Biotech #Oncology
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
September 4, 2026 at 8:03 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global finance experience to support its capital strategy and BiTAC cancer therapy platform. #Biotech #Oncology
#VRXA VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 4, 2026 at 11:00 AM
#VRXA VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
https://www.stocktitan.net/news/VRXA/veraxa-biotech-appoints-raju-willener-as-chief-financial-sq9w6gd5y206.html
We’re delighted to welcome Raju Willener, MBA, MA, as our new Chief Financial Officer! His strategic expertise will help advance our BiTAC® platform and shift our pipeline toward the clinic.
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
September 4, 2026 at 12:30 PM
We’re delighted to welcome Raju Willener, MBA, MA, as our new Chief Financial Officer! His strategic expertise will help advance our BiTAC® platform and shift our pipeline toward the clinic.
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
For more see: bit.ly/3Tb45pK
#$VRXA #Biotech #ADCs #TCEs
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) and Secarna report early positive results from their AOC collaboration, showing greater potency than unconjugated oligonucleotides in autoimmune disease research. A promising step for next-gen therapeutics. #Biotech #Immunology
August 27, 2026 at 11:12 AM
VERAXA Biotech (NASDAQ: VRXA) and Secarna report early positive results from their AOC collaboration, showing greater potency than unconjugated oligonucleotides in autoimmune disease research. A promising step for next-gen therapeutics. #Biotech #Immunology
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
August 27, 2026 at 11:13 AM
VERAXA Biotech (NASDAQ: VRXA) receives favorable regulatory guidance from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially clearing the path toward clinical trials. Preclinical data showed selective dual-biomarker cancer cell targeting. #Oncology #Biotech
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech
August 27, 2026 at 11:18 AM
VERAXA Biotech (NASDAQ: VRXA) advances its dual-targeting BiTAC cancer platform, with its lead T-cell engager nearing IND-enabling studies and VXA-222 bispecific ADC moving past discovery. 50+ patents support a growing oncology pipeline. #Oncology #Biotech